CO2017009954A2 - Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina - Google Patents
Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúminaInfo
- Publication number
- CO2017009954A2 CO2017009954A2 CONC2017/0009954A CO2017009954A CO2017009954A2 CO 2017009954 A2 CO2017009954 A2 CO 2017009954A2 CO 2017009954 A CO2017009954 A CO 2017009954A CO 2017009954 A2 CO2017009954 A2 CO 2017009954A2
- Authority
- CO
- Colombia
- Prior art keywords
- repeats
- designed
- binding specificity
- ankyrine
- domains
- Prior art date
Links
- 102000007562 Serum Albumin Human genes 0.000 title abstract 2
- 108010071390 Serum Albumin Proteins 0.000 title abstract 2
- 102000023732 binding proteins Human genes 0.000 abstract 5
- 108091008324 binding proteins Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 abstract 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
Abstract
Se describen nuevos dominios diseñados con repeticiones de anquirina con especificidad de unión para seroalbúmina, proteínas de unión recombinantes que comprenden al menos dos dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina, así como proteínas de unión recombinantes que comprenden al menos un dominio diseñado con repeticiones de anquirina con especificidad de unión para el factor de crecimiento del hepatocito (HGF), al menos un dominio diseñado con repeticiones de anquirina con especificidad de unión para el factor de crecimiento endotelial vascular (VEGF-A) y al menos dos dominios diseñados con repeticiones de anquirina con especificidad de unión para seroalbúmina, así como ácidos nucleicos que codifican dichos dominios diseñados con repeticiones de anquirina y proteínas de unión recombinantes, composiciones farmacéuticas que comprenden dichos dominios diseñados con repeticiones de anquirina, proteínas de unión recombinantes o ácidos nucleicos y el uso de dichos dominios diseñados con repeticiones de anquirina, proteínas de unión recombinantes, ácidos nucleicos o composiciones farmacéuticas en el tratamiento de enfermedades.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15162511 | 2015-04-02 | ||
| EP15162502 | 2015-04-02 | ||
| PCT/EP2016/057272 WO2016156596A1 (en) | 2015-04-02 | 2016-04-01 | Designed ankyrin repeat domains with binding specificity for serum albumin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017009954A2 true CO2017009954A2 (es) | 2018-02-20 |
Family
ID=55650423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0009954A CO2017009954A2 (es) | 2015-04-02 | 2017-09-29 | Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9458211B1 (es) |
| EP (2) | EP3277711B9 (es) |
| JP (1) | JP6552636B2 (es) |
| KR (2) | KR20220109488A (es) |
| CN (1) | CN107454904A (es) |
| AU (3) | AU2016240220B2 (es) |
| BR (1) | BR112017020986A2 (es) |
| CA (1) | CA2979602C (es) |
| CL (1) | CL2017002454A1 (es) |
| CO (1) | CO2017009954A2 (es) |
| ES (1) | ES2953482T3 (es) |
| HK (1) | HK1244009A1 (es) |
| IL (2) | IL276944B (es) |
| MX (2) | MX2022008302A (es) |
| MY (1) | MY179505A (es) |
| NZ (1) | NZ735803A (es) |
| PH (1) | PH12017501792A1 (es) |
| RU (1) | RU2769470C2 (es) |
| SA (1) | SA517390092B1 (es) |
| SG (1) | SG11201707606RA (es) |
| WO (1) | WO2016156596A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007116360A2 (en) | 2006-04-07 | 2007-10-18 | The Procter & Gamble Company | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
| CA2818990C (en) * | 2010-11-26 | 2021-06-15 | Molecular Partners Ag | Designed repeat proteins binding to serum albumin |
| EP3487518A4 (en) | 2016-07-20 | 2020-08-12 | Aerpio Therapeutics LLC | HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS) |
| MX2019003298A (es) | 2016-09-22 | 2019-09-26 | Molecular Partners Ag | Proteinas de union recombinantes y sus usos. |
| WO2019011167A1 (zh) * | 2017-07-12 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | 双特异性重组蛋白 |
| WO2019034332A1 (en) * | 2017-08-18 | 2019-02-21 | Cambridge Enterprise Limited | MODULAR BINDING PROTEINS |
| JP2022502367A (ja) | 2018-09-24 | 2022-01-11 | エアーピオ ファーマシューティカルズ， インコーポレイテッド | ＨＰＴＰ−β（ＶＥ−ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体 |
| EP3941580A1 (en) * | 2019-03-22 | 2022-01-26 | Reflexion Pharmaceuticals, Inc. | D-peptidic compounds for vegf |
| US20220298212A1 (en) | 2019-06-04 | 2022-09-22 | Molecular Partners Ag | Recombinant 4-1bb binding proteins and their use |
| CA3139051A1 (en) * | 2019-06-04 | 2020-12-10 | Christian REICHEN | Multispecific proteins |
| BR112021024231A2 (pt) * | 2019-06-04 | 2022-04-26 | Molecular Partners Ag | Proteínas de ligação fap recombinantes e uso da mesma |
| WO2020245171A1 (en) | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Designed ankyrin repeat domain with improved stability |
| US20230041822A1 (en) | 2019-12-11 | 2023-02-09 | Molecular Partners Ag | Recombinant peptide-mhc complex binding proteins and their generation and use |
| AU2020399230A1 (en) | 2019-12-11 | 2022-06-23 | Molecular Partners Ag | Recombinant peptide-MHC complex binding proteins and their generation and use |
| CR20220618A (es) | 2020-05-06 | 2023-01-19 | Molecular Partners Ag | Nuevas proteinas de unión a repeticiones de anquirina y sus usos |
| BR112022023049A2 (pt) | 2020-05-14 | 2022-12-20 | Molecular Partners Ag | Proteínas multiespecíficas |
| AU2021271131A1 (en) | 2020-05-14 | 2022-12-15 | Molecular Partners Ag | Recombinant CD40 binding proteins and their use |
| EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| AU2021403833A1 (en) | 2020-12-16 | 2023-07-27 | Molecular Partners Ag | Novel slow-release prodrugs |
| MX2023007067A (es) | 2020-12-16 | 2023-08-09 | Molecular Partners Ag | Proteinas recombinantes de union a cd3 y su uso. |
| AU2022233791A1 (en) | 2021-03-09 | 2023-09-28 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| AU2022231913A1 (en) | 2021-03-09 | 2023-09-28 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| MX2023010543A (es) | 2021-03-09 | 2023-10-13 | Molecular Partners Ag | Ligadores multiespecificos de celulas t novedosos basados en darpin. |
| WO2022190008A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Protease cleavable prodrugs |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| CN114957426B (zh) * | 2022-06-02 | 2023-05-16 | 华南师范大学 | Sp6rars及其在防治蜚蠊目昆虫中的应用 |
| WO2024028278A1 (en) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EA013615B1 (ru) | 2004-11-12 | 2010-06-30 | Байер Шеринг Фарма Акциенгезельшафт | Рекомбинантный онколитический парамиксовирус и его применение |
| EP2365000A3 (en) | 2005-05-18 | 2013-01-16 | Ablynx N.V. | Improved nanobodiesTM against tumor necrosis factor-alpha |
| NZ564695A (en) | 2005-07-08 | 2009-02-28 | Univ Zuerich | Phage display using cotranslational translocation of fusion polypeptides |
| WO2007103455A2 (en) | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Genetic packages and uses thereof |
| SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| JP2010539915A (ja) | 2007-09-24 | 2010-12-24 | ユニバーシティ・オブ・チューリッヒ | 設計されたアルマジロリピートタンパク質 |
| JP5954990B2 (ja) | 2008-11-03 | 2016-07-20 | モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ | Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質 |
| CA2788993A1 (en) | 2010-02-05 | 2011-08-11 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| AR081361A1 (es) * | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| NZ604805A (en) * | 2010-07-09 | 2014-09-26 | Affibody Ab | Polypeptides |
| EP2824457A1 (en) * | 2010-07-19 | 2015-01-14 | F. Hoffmann-La Roche AG | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| BR112013013003A2 (pt) * | 2010-11-24 | 2016-08-09 | Glaxo Group Ltd | proteína de ligação de antígeno, e, composição farmacêutica |
| CA2818990C (en) * | 2010-11-26 | 2021-06-15 | Molecular Partners Ag | Designed repeat proteins binding to serum albumin |
| EP2702069A4 (en) | 2011-04-29 | 2015-04-29 | Janssen Biotech Inc | IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF |
| BR112014032316A2 (pt) | 2012-06-28 | 2017-06-27 | Molecular Partners Ag | proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| WO2014191574A1 (en) * | 2013-05-31 | 2014-12-04 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
-
2016
- 2016-04-01 ES ES16713904T patent/ES2953482T3/es active Active
- 2016-04-01 KR KR1020227025940A patent/KR20220109488A/ko not_active Application Discontinuation
- 2016-04-01 US US15/089,014 patent/US9458211B1/en active Active
- 2016-04-01 RU RU2017134456A patent/RU2769470C2/ru active
- 2016-04-01 BR BR112017020986-1A patent/BR112017020986A2/pt active Search and Examination
- 2016-04-01 MX MX2022008302A patent/MX2022008302A/es unknown
- 2016-04-01 JP JP2017551176A patent/JP6552636B2/ja active Active
- 2016-04-01 NZ NZ735803A patent/NZ735803A/en unknown
- 2016-04-01 CA CA2979602A patent/CA2979602C/en active Active
- 2016-04-01 EP EP16713904.7A patent/EP3277711B9/en active Active
- 2016-04-01 SG SG11201707606RA patent/SG11201707606RA/en unknown
- 2016-04-01 EP EP23177745.9A patent/EP4272838A3/en active Pending
- 2016-04-01 WO PCT/EP2016/057272 patent/WO2016156596A1/en active Application Filing
- 2016-04-01 CN CN201680019907.XA patent/CN107454904A/zh active Pending
- 2016-04-01 KR KR1020177030096A patent/KR102427117B1/ko active IP Right Grant
- 2016-04-01 MX MX2017012485A patent/MX2017012485A/es unknown
- 2016-04-01 MY MYPI2017703637A patent/MY179505A/en unknown
- 2016-04-01 IL IL276944A patent/IL276944B/en unknown
- 2016-04-01 AU AU2016240220A patent/AU2016240220B2/en active Active
- 2016-08-26 US US15/248,731 patent/US10155791B2/en active Active
-
2017
- 2017-09-28 IL IL254788A patent/IL254788B/en active IP Right Grant
- 2017-09-28 CL CL2017002454A patent/CL2017002454A1/es unknown
- 2017-09-28 PH PH12017501792A patent/PH12017501792A1/en unknown
- 2017-09-29 CO CONC2017/0009954A patent/CO2017009954A2/es unknown
- 2017-10-02 SA SA517390092A patent/SA517390092B1/ar unknown
-
2018
- 2018-03-12 HK HK18103392.8A patent/HK1244009A1/zh unknown
- 2018-11-02 US US16/178,923 patent/US11332501B2/en active Active
-
2020
- 2020-02-21 AU AU2020201264A patent/AU2020201264A1/en not_active Abandoned
-
2021
- 2021-12-17 AU AU2021286418A patent/AU2021286418B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017009954A2 (es) | Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina | |
| CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| UY35407A (es) | ?PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO?. | |
| BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
| GEP20227447B (en) | Constructs having sirp-alpha domain or variant thereof | |
| BR112017010088A2 (pt) | polinucleotídeo modulatório, pré-micro-rna artificial, vírus recombinante de aav, composição compreendendo o plasmídeo ou vetor, kit compreendendo o referido plasmídeo ou vetor e uso do mesmo | |
| BR112018072915A2 (pt) | peptídeo cíclico isolado e composição farmacêutica | |
| BR112019001737A2 (pt) | expressão de pten-long com vírus oncolíticos | |
| EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
| BR112017014615A2 (pt) | proteínas de fusão de multi-direcionamento e seus usos | |
| EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
| EA202191513A1 (ru) | Снижение вязкости фармацевтических составов | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| BR112019010128A2 (pt) | proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas | |
| CO2017011583A2 (es) | Polipéptidos dirigidos a la fusión de vih | |
| MX2021014649A (es) | Dominio de repetición de anquirina diseñado con estabilidad mejorada. | |
| TW201713686A (en) | Methods for preparing modified von Willebrand factor | |
| DK3399040T3 (da) | Fremgangsmåde til fremstilling af porcine circovirus type 2 capsid-protein og farmaceutisk sammensætning omfattende samme | |
| BR112017000710A2 (pt) | polipeptídeo isolado, polipeptídeo modificado de revestimento final isolado, composição de matéria, polipeptídeo de fusão isolado, composição farmacêutica, método de tratamento de uma doença inflamatória, uso do polipeptídeo isolado, polinucleotídeo isolado, estrutura de ácido nucleico, e método de determinação da potência de um lote do polipeptídeo isolado | |
| BR112016002570A2 (pt) | alvos moleculares para o tratamento de feridas, em particular, feridas crônicas | |
| CL2016002361A1 (es) | Compuestos derivados de azabenzofurano; composición farmacéutica, y su uso como inhibidores de la función de la proteína ns5b del hcv para el tratamiento de la hepatitis c. | |
| BR112017004008A2 (pt) | polipeptídeo recombinante, sequência de ácido nucleico, célula hospedeira, bionanopartícula, métodos para produção de uma bionanopartícula e para tratamento ou prevenção do vírus da dengue, e, vacina. | |
| AR099641A1 (es) | OSTEONECTINA (SPARC) COMO BLANCO TERAPÉUTICO PARA EL TRATAMIENTO Y PREVENCIÓN DEL FALLO HEPÁTICO AGUDO, COMPOSICIÓN FARMACEUTICA, CONSTRUCTO GENÉTICO, ARNsi, AGENTE QUE INHIBE LA EXPRESIÓN, USO | |
| EA201692161A1 (ru) | Прогемостатические белки для лечения кровотечений |